Incidence of Acute Kidney Injury Among Patients Receiving the Combination of Vancomycin with Piperacillin-Tazobactam or Meropenem
Related Experiment Video
Updated: Feb 5, 2026

Ischemia-reperfusion Model of Acute Kidney Injury and Post Injury Fibrosis in Mice
Published on: August 9, 2013
Amy D Robertson1,2, Chenghui Li3, Drayton A Hammond4
1Department of Pharmacy Practice, University of Arkansas for Medical Sciences Northwest Regional Campus, Fayetteville, Arkansas.
Introduction:
Vancomycin (VAN) is associated with an increased risk of acute kidney injury (AKI). Evidence is conflicting regarding the risk of AKI when VAN is combined with an antipseudomonal β-lactam.
Objectives:
To determine the comparative incidence of AKI when VAN is combined with piperacillin-tazobactam (PTZ) or meropenem (MER).
Methods:
This was a retrospective cohort study of acutely ill adults receiving the combination of VAN and PTZ or MER for at least 48 hours between November 1, 2014, and October 31, 2016, in a tertiary care hospital. Critically ill patients and those with baseline renal dysfunction were excluded. The primary outcome was the incidence of AKI during or within 72 hours of completing antibiotic therapy, defined as an absolute increase in serum creatinine (Scr ) of 0.5 mg/dl or higher or a 50% or more increase in Scr from baseline. Secondary outcomes included time to AKI development, duration of AKI, and length of hospitalization. Continuous variables were assessed using the Wilcoxon rank sum or the Student t test; categorical variables were assessed using χ2 or Fisher exact tests. Independent risk factors for the development of AKI were also examined.
Results:
A total of 169 patients were evaluated. A significantly higher incidence of AKI was observed in the PTZ group compared with MER (16.5% vs 3.6%; p=0.009). The median time to AKI onset was significantly shorter with PTZ compared with MER (3 vs 7 days; p=0.009). After adjusting for baseline differences, VAN/PTZ was associated with a 6.8-fold increased risk of developing AKI (odds ratio [OR] 6.8, 95% confidence interval [CI] 1.5-30.9) compared with VAN/MER. VAN doses higher than 4 g/day and trough levels higher than 20 μg/ml were independent risk factors for developing AKI (OR 8.7, 95% CI 1.04-72.94, and OR 9.01, 95% CI 1.44-56.21, respectively).
Conclusion:
The combination of VAN/PTZ increases the risk of AKI when compared with VAN/MER in acutely ill adults.
Insights
Vancomycin combined with piperacillin-tazobactam (PTZ) significantly increases acute kidney injury (AKI) risk compared to vancomycin with meropenem (MER). This finding is crucial for managing infections and preventing kidney damage in acutely ill patients.
Area of Science:
- Nephrology and Infectious Diseases
- Clinical Pharmacology and Therapeutics
Background:
- Vancomycin (VAN) use is linked to acute kidney injury (AKI).
- Conflicting evidence exists regarding the AKI risk when VAN is combined with antipseudomonal β-lactams.
Purpose of the Study:
- To compare the incidence of AKI in acutely ill adults receiving VAN combined with piperacillin-tazobactam (PTZ) versus meropenem (MER).
Main Methods:
- Retrospective cohort study of 169 adult patients receiving VAN/PTZ or VAN/MER for ≥48 hours.
- Exclusion of critically ill patients and those with baseline renal dysfunction.
- Primary outcome: AKI incidence defined by serum creatinine increase; secondary outcomes: time to AKI, duration, and hospitalization length.
Main Results:
- AKI incidence was significantly higher with VAN/PTZ (16.5%) compared to VAN/MER (3.6%).
- Time to AKI onset was shorter with VAN/PTZ (3 days) versus VAN/MER (7 days).
- VAN/PTZ was associated with a 6.8-fold increased risk of AKI after adjustment.
Conclusions:
- The combination of VAN/PTZ increases the risk of AKI compared to VAN/MER in acutely ill adults.
- High VAN doses (>4 g/day) and trough levels (>20 μg/ml) were independent risk factors for AKI.
Related Concept Videos
Acute Kidney Injury I: Introduction
Acute Kidney Injury II: Pathophysiology
Acute Kidney Injury VI: Nursing Management
Acute Kidney Injury V: Interprofessional Care
Acute Kidney Injury III: Clinical Manifestations
Acute Kidney Injury IV: Diagnostic Studies and Prevention

